Mosunetuzumab Conditional Approval Further Validates Bispecific Antibodies Development

Mosunetuzumab Approval In USA & Other Markets In Next 2-3 Years To Drive Bispecific Antibodies Cumulative Sales To USD 60 Billion By 2028 Says Kuick Research


Bispecific antibodies are the advanced form of antibodies which have transformed the management of chronic disorders including cancer. The bispecific antibody is novel class of therapeutic antibodies which can simultaneously bind two separate and unique antigens. The dual specificity of the construct opens a wide range of opportunities for the researchers and can be exploited to target two different signaling pathways simultaneously, dual targeting of different disease mediators, and delivering payloads to target site. In addition this, the small size of bispecific antibodies not only enables it to pass through blood brain barrier but also smoothens the manufacturing process.


Global Bispecific Antibody Market Insight 2028 Report Highlights:


  • Global Bispecific Antibody Market Growth Rate:  100% CAGR (2016 -2021)
  • Approved Bispecific Antibodies In Market: 4 Antibodies
  • Detailed Market Sales and Trends Insight Till 2028
  • Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022
  • Global and Regional Market Analysis
  • Approved Drug Sales Forecast Till 2028
  • Ongoing Clinical Trials Assessment by Status, Phase and Region


Download Report:


Since the introduction of Blincyto in 2014, the cancer bispecific antibody market is growing with high rates which can be justified by the ever increasing sales of Blincyto. Apart from this, three other bispecific antibodies including Hemlibra, Rybrevant, and Vabsmyo have also gained approval by regulatory bodies. Currently, Hmelibra is occupying 80% of the global market share which is mainly due to rising awareness among individuals, surge in prevalence of hemophilia, and favorable reimbursement policies. For instance, Hemlibra Co-Pay Program in US allows eligible commercially insured patients to pay as little as US$ 5 for the drug.


Although cancer bispecific antibodies hold a small share in the global market, it is expected that this segment will constitute significant share during the forthcoming years which is mainly attributed to rapid adoption of Rybrevant in the global market. Moreover, the pipeline is highly crowded which points towards positive future of bispecific antibodies in the management of cancer. Mosunetuzumab developed by Biogen is a CD20xCD3 T-cell engaging bispecific antibody in development for the treatment of people with B-cell non-Hodgkin’s lymphoma (NHL), including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Recently in 2022, European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted conditional marketing approval to Mosunetuzumab for the management of patients with relapsed or refractory (R/R) Follicular Lymphoma (FL), who have received at least two prior systemic therapies.


With coming of the new technology and more of research in this segment around 50 different formats of bispecific antibody production have been discovered and patented by big pharma ventures. Production of CrossMabs, Diabodies, Nano bodies, Bispecific T-cell engager antibodies (BiTEs), dual-variable-domain immunoglobulin (DVD-Ig™) are some of the most employed and significant techniques. The enhanced specificity and efficacy of these molecules is no doubt gaining the interest of numerous scientists, pharma and biotechnological companies.


Since their entry into the market, the bispecific antibodies have shown cumulative sales of US$ 9 Billion by 2021, which is expected to surpass US$ 60 Billion by 2028 thus indicating huge potential of this segment in overall pharmaceutical market. The promising pipeline of bispecific antibodies suggests that about 4-6 bispecific antibodies will gain entry into the market in next 5 years which will further drive the growth of market. The major key players in the market include Amgen, Gilead Science, Roche, Zai Lab, Beigene, Akeso, Innovent Biologics, and Novartis which actively invest in research and development of this therapeutics.  


As per our report findings, the global bispecific antibody market annual sales is expected to surpass US$ 25 Billion by 2028. The considerable rise in the geriatric population along with shift towards sedentary lifestyle increases the risk of developing the cancer and other chronic diseases. Moreover, the unavailability of effectively curing drugs and the rate at which conventional therapies are failing possess an unmet need for the development of targeted therapies which will boost the growth of the market. Geographically, US is expected to dominate the market for next few years attributing to the presence of large pharmaceutical sector and increasing awareness among the population for novel therapies.



Neeraj Chawla

Kuick Research

Research Head



Back to news